Literature DB >> 25661477

Long-term data from the Swiss pulmonary hypertension registry.

Séverine Mueller-Mottet1, Hans Stricker, Guido Domenighetti, Guido Domeninghetti, Andrea Azzola, Thomas Geiser, Markus Schwerzmann, Daniel Weilenmann, Otto Schoch, Jean-Marc Fellrath, Thierry Rochat, Frederic Lador, Maurice Beghetti, Laurent Nicod, John-David Aubert, Vladimir Popov, Rudolf Speich, Stephan Keusch, Elisabeth Hasler, Lars C Huber, Peter Grendelmeier, Michael Tamm, Silvia Ulrich.   

Abstract

BACKGROUND: Registries are important for real-life epidemiology on different pulmonary hypertension (PH) groups.
OBJECTIVE: To provide long-term data of the Swiss PH registry of 1998-2012.
METHODS: PH patients have been classified into 5 groups and registered upon written informed consent at 5 university and 8 associated hospitals since 1998. New York Heart Association (NYHA) class, 6-min walk distance, hemodynamics and therapy were registered at baseline. Patients were regularly followed, and therapy and events (death, transplantation, endarterectomy or loss to follow-up) registered. The data were stratified according to the time of diagnosis into prevalent before 2000 and incident during 2000-2004, 2005-2008 and 2009-2012.
RESULTS: From 996 (53% female) PH patients, 549 had pulmonary arterial hypertension (PAH), 36 PH due to left heart disease, 127 due to lung disease, 249 to chronic thromboembolic PH (CTEPH) and 35 to miscellaneous PH. Age and BMI significantly increased over time, whereas hemodynamic severity decreased. Overall, event-free survival was 84, 72, 64 and 58% for the years 1-4 and similar for time periods since 2000, but better during the more recent periods for PAH and CTEPH. Of all PAH cases, 89% had target medical therapy and 43% combination therapy. Of CTEPH patients, 14 and 2% underwent pulmonary endarterectomy or transplantation, respectively; 87% were treated with PAH target therapy.
CONCLUSION: Since 2000, the incident Swiss PH patients registered were older, hemodynamically better and mostly treated with PAH target therapies. Survival has been better for PAH and CTEPH diagnosed since 2008 compared with earlier diagnosis or other classifications.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25661477     DOI: 10.1159/000370125

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  23 in total

Review 1.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 2.  Epidemiology and treatment of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Eleni Giannoulatou; David S Celermajer; Marc Humbert
Journal:  Nat Rev Cardiol       Date:  2017-06-08       Impact factor: 32.419

3.  Pulmonary arterial hypertension in the elderly: Clinical perspectives.

Authors:  Nicholas Rothbard; Abhinav Agrawal; Conrad Fischer; Arunabh Talwar; Sonu Sahni
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

4.  Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors.

Authors:  Aaron W Trammell; Amit J Shah; Lawrence S Phillips; C Michael Hart
Journal:  Pulm Circ       Date:  2019 Jan-Mar       Impact factor: 3.017

5.  Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism.

Authors:  Nicolas Coquoz; Daniel Weilenmann; Daiana Stolz; Vladimir Popov; Andrea Azzola; Jean-Marc Fellrath; Hans Stricker; Alberto Pagnamenta; Sebastian Ott; Silvia Ulrich; Sandor Györik; Jérôme Pasquier; John-David Aubert
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

6.  Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.

Authors:  Paula Appenzeller; Mona Lichtblau; Charlotte Berlier; John-David Aubert; Andrea Azzola; Jean-Marc Fellrath; Thomas Geiser; Frederic Lador; Susanne Pohle; Isabelle Opitz; Markus Schwerzmann; Hans Stricker; Michael Tamm; Stéphanie Saxer; Silvia Ulrich
Journal:  Pulm Circ       Date:  2022-01-05       Impact factor: 2.886

7.  Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Daniel P Cook; Meng Xu; Victoria L Martucci; Jeffrey S Annis; Melinda C Aldrich; Anna R Hemnes; Evan L Brittain
Journal:  Pulm Circ       Date:  2022-01-03       Impact factor: 2.886

8.  Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH.

Authors:  Elena Pfeuffer; Holger Krannich; Michael Halank; Heinrike Wilkens; Philipp Kolb; Berthold Jany; Matthias Held
Journal:  Lung       Date:  2017-10-09       Impact factor: 2.584

Review 9.  Pulmonary hypertension in the elderly: a different disease?

Authors:  Grégory Berra; Stéphane Noble; Paola M Soccal; Maurice Beghetti; Frédéric Lador
Journal:  Breathe (Sheff)       Date:  2016-03

10.  Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe.

Authors:  Andris Skride; Kristaps Sablinskis; Aivars Lejnieks; Ainars Rudzitis; Irene Lang
Journal:  Pulm Circ       Date:  2018-05-16       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.